H.C. Wainwright raised the firm’s price target on Stoke Therapeutics (STOK) to $50 from $35 and keeps a Buy rating on the shares. The firm says zorevunersen’s “clinically transformative” 82% seizure reduction and “significant” cognitive gains substantially de-risk the Phase 3 EMPEROR study “which is powered for far more modest improvements.” The analyst received “strong” validation from key opinion leaders supporting its use in severe patients despite safety signals. The new data expande the addressable market to “Atypical Dravet,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting
- Biogen, Stoke Therapeutics announce data presentations for zorevunersen
- Stoke, Biogen present zorevunersen data at American Epilepsy Society
- Biogen, Stoke Therapeutics announce publication of data from BUTTERFLY study
- Stoke Therapeutics, Biogen publish final data from BUTTERFLY study